scholarly journals Hif1α down-regulation is associated with transposition of great arteries in mice treated with a retinoic acid antagonist

BMC Genomics ◽  
2010 ◽  
Vol 11 (1) ◽  
pp. 497 ◽  
Author(s):  
Francesca Amati ◽  
Laura Diano ◽  
Luisa Campagnolo ◽  
Lucia Vecchione ◽  
Daria Cipollone ◽  
...  
1996 ◽  
Vol 271 (11) ◽  
pp. 6502-6508 ◽  
Author(s):  
Giorgio Scita ◽  
Nadine Darwiche ◽  
Eileen Greenwald ◽  
Miriam Rosenberg ◽  
Katerina Politi ◽  
...  

Hepatology ◽  
1999 ◽  
Vol 29 (4) ◽  
pp. 1091-1098 ◽  
Author(s):  
Dae-Ghon Kim ◽  
Dae-yeol Lee ◽  
Baik-Hwan Cho ◽  
Kyung-Ran You ◽  
Mi-Young Kim ◽  
...  

Blood ◽  
2001 ◽  
Vol 97 (8) ◽  
pp. 2449-2456 ◽  
Author(s):  
Pierre G. Lutz ◽  
Anne Houzel-Charavel ◽  
Christel Moog-Lutz ◽  
Yvon E. Cayre

Abstract A pivotal role has been assigned to Myb in the control of myeloid cell growth. Although Myb is a target of retinoic acid, little is known about the mechanisms by which it may contribute to induced growth arrest in leukemia cells. Indeed, few Myb target genes are known to be linked to proliferation. Myeloblastin is involved in the control of proliferation in myeloid leukemia cells. It is expressed early during hematopoiesis and is a granulocyte colony-stimulating factor–responsive gene. Myeloblastin can confer factor-independent growth to hematopoietic cells, an early step in leukemia transformation. The myeloblastin promoter contains PU.1, C/EBP, and Myb binding sites, each of which are critical for constitutive expression in myeloid cells. Inhibition of myeloblastin expression in leukemia cells growth-arrested by retinoic acid is demonstrated to depend on Myb down-regulation. Myb is shown to induce myeloblastin expression and abolish its down-regulation by retinoic acid. Altogether, the data offer a clue as to how a myeloid-specific transcriptional machinery can be accessible to regulation by retinoic acid and point to myeloblastin as a novel target of Myb. This link between Myb and myeloblastin suggests a previously nonidentified Myb pathway through which growth arrest is induced by retinoic acid in myeloid leukemia cells.


2008 ◽  
Vol 42 (3) ◽  
pp. 249-260 ◽  
Author(s):  
Bogusz Trojanowicz ◽  
Anja Winkler ◽  
Kathrin Hammje ◽  
Zhouxun Chen ◽  
Carsten Sekulla ◽  
...  

Retinoic acid (RA) acts as an anti-proliferative and redifferentiation agent in the therapy of thyroid carcinoma. Our previous studies demonstrated that pretreatment of follicular thyroid carcinoma cell lines FTC-133 and FTC-238 resulted in decreased in vitro proliferation rates and reduced tumor cell growth of xenotransplants. In addition to the previous results, we found that RA led to decreased vitality and invasiveness of FTC-133 and FTC-238 cells as they reacted with reduction of intracellular ATP levels and number of migrated cells respectively. However, the molecular mechanisms by which RA mediates these effects are not well understood. Two-dimensional (2D) screening of the proteins related to ATP metabolism and western blot analysis revealed α-enolase (ENO1) to be down-regulated in FTC-133 and FTC-238 cells after RA treatment. 2D gel detection and mass spectrometric analysis revealed that ENO1 existed as three separate protein spots of distinct pIs (ENO1–A1–A3). Comparative 2D difference gel electrophoresis analysis of fluorescently labeled protein samples of RA-treated and untreated FTC-133 demonstrated a selective down-regulation of ENO1-A1 which we identified as a phosphoprotein. RA caused the dephosphorylation of ENO1-A1. Both, RA-mediated and specific knock-down of ENO1/MBP-1 resulted in the reduction of MYC oncoprotein, and simultaneously decreased proliferation rates of FTC-133 and FTC-238 cell lines. In summary, the RA-mediated down-regulation of the ENO1 gene products and MYC oncoprotein provides a novel molecular mechanism facilitating the anti-proliferative effect of RA in human thyroid carcinoma cells and suggests new pathways for supportive RA therapies.


Sign in / Sign up

Export Citation Format

Share Document